Amgen Builds Up Future Launches As Oncology Biosimilars Slide
Firm Looks To Amjevita, Along With Stelara And Eylea Rivals, For Future Growth
Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.
You may also be interested in...
Pfizer Quietly Chalks Up Another $2bn Year For Biosimilars
Despite annual sales that topped out at more than $2bn, Pfizer remains tight-lipped about its biosimilars interests as it looks towards a US launch this year of its Abrilada rival to Humira.
Amgen Sued On US Stelara Biosimilar After Providing May 2023 Intent
With Janssen’s Stelara set to lose its exclusivity in September 2023, the originator is looking to ward off potential biosimilar competition from Amgen by suing the firm for patent infringement in a US district court.
‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars
With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is “doing better, but we still have improvements to make.”